Navigation Links
NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis
Date:10/30/2009

manifestations of the infection often have adverse social and occupational ramifications for affected patients. As such, onychomycosis is an infection that warrants an effective medical treatment. According to Podiatry Today, over 35 million people in the United States have onychomycosis. Estimates indicate that up to 50% of those affected by the disease do not receive treatment. Systemic treatments represent well over 80% of the market today, but have potential severe liver toxicity issues, and have shown to have relapse rates of 40% or higher.

About Aganocide Compounds

The Aganocide compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay to mimic the body's natural defense against infection. The Aganocide compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated, first-in-class, small molecule, patented new chemical entities may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of antibiotic-resistant bacterial strains. In preclinical testing, the Aganocide compounds have been shown to be highly effective against bacteria, including its multi-drug resistant strains (such as MRSA), viruses and fungi. They also have been demonstrated to be effective against bacteria in biofilms, which render most antibiotics ineffective. Aganocides have a broad therapeutic index while providing a high degree of potency and tolerability as well as dosing versatility and flexibility.

About NovaBay

NovaBay Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Frost & Sullivan Awards Agfa Healthcare for Brazilian Market Penetration Leadership in 2009
2. Milestone Scientific Expands Global Sales Strategy to Enhance Penetration of International Dental Markets
3. Premature ejaculation spray enables men to last 6 times longer after penetration
4. Lumension Security Receives Frost & Sullivan 2008 Global Market Penetration Leadership Award
5. OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration
6. Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients
7. LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
8. Advanced Life Sciences Restanza Demonstrates Efficacy in Treating Anthrax Infection
9. 96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy
10. -Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-
11. Econiche(TM) Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... PINES, FL (PRWEB) June 03, 2015 The ... event as part of the Veterans Health Administration’s (VHA) National ... place in the JC Cobb room located on the first ... 10:00 a.m. to 4:00 p.m. Women Veterans and their ... are invited to attend. To download a printable event flyer, ...
(Date:6/3/2015)... Norcross, GA (PRWEB) June 03, 2015 ... officially named the winner of its 2015 U.S. Education ... Power Portfolio in a college or university in the ... a GIScience student focused on Remote Sensing and Civil ... winning study, titled, “Pavement Surface Cracks Detection and Assessment ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Johnson & ... pay $7.8 million to resolve a Risperdal lawsuit ( ... tactics the company allegedly used to market the antipsychotic ... Court indicate that the Arkansas Attorney General moved to ... the accord. The Risperdal settlement amounts to just a ...
(Date:6/3/2015)... 2015 On June 22, 2015, Medicare ... drug sensitivity (pharmacogenetic) testing that it has reimbursed since 2009. ... as 19 million of the 49 million Medicare beneficiaries in ... life-threatening adverse drug events.(1) Sadly, if it became a standard ... Medicine, the use of an individual’s genetic information to tailor ...
(Date:6/3/2015)... Array Health , a leading ... that CEO Jonathan Rickert will present at America’s ... 4, 2015. The session will address the how the ... business models in health care, and why they are ... Digital Transformation and the Health Care Enterprise: Driving Business ...
Breaking Medicine News(10 mins):Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 2Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 3Health News:Hexagon Geospatial Announces U.S. Education Challenge Winner at HxGN Live 2015 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... the pain-balm segment, with a market share of 70 ... Amrutanjan, Tiger Balm (locally manufactured by Elder Pharma), Zandu ... SmithKline India (GSK) has decided to transfer its Iodex ... a GSK subsidiary. SKBCH has a strong marketing and ...
... the most common cancer among women. It accounts for ... more than 23,000 new cases diagnosed in 2001. Progestin ... the highest// level of protection against ovarian cancer. Analysis ... study showed that the pill can help prevent ovarian ...
... disease that affects at least 39 million Americans, and ... to describe the problem. One in five Americans is ... raises the risk of many potentially fatal health conditions//, ... is linked to at least 300,000 deaths in the ...
... studying eight cross-gender heart transplants from New York Medical ... the heart after injury.// The research explodes the long-standing ... finding has implications for heart disease treatment. ... damaged heart much as it does other organs came ...
... non-steroidal anti-inflammatory drug (NSAID) treatment has shown that ... the risk of ulcer formation.// Treatment with omeprazole ... infections and reduced the six-month ulcer probability of ... to 12 per cent in the NSAID-treated arthritis ...
... discovered molecules in the body that can protect ... research, the research could potentially lead to the ... been linked with ailments such as cardiovascular disease, ... and Alzheimer’s disease. ,The researchers from ...
Cached Medicine News:
(Date:6/3/2015)... 2015  SurgiQuest®, Inc. ("SurgiQuest", the "Company"), a ... invasive surgery (MIS) announced today that surgeons have ... procedures.  Adoption has risen rapidly with a 150% ... by the company,s expansion from robotics into the ... to over 45 countries.   The ...
(Date:6/3/2015)... , June 02, 2015 Research and ... of the "Global Neurodegenerative Diseases Market 2015-2019" ... global neurodegenerative diseases market to grow at a ... This report covers the present scenario and ... market for the period 2015-2019. To calculate the ...
(Date:6/3/2015)... 2015  EIP Pharma LLC ( www.eippharma.com ) today ... of VX-745 in Alzheimer,s disease (AD) is underway.  VX-745 ... inhibitor of the alpha isoform of the protein enzyme ... "Recent human genetic data demonstrate that inflammation is ... Alzheimer,s, while the science also indicates the p38 MAPK ...
Breaking Medicine Technology:Rapid Procedure Growth With SurgiQuest's AirSeal System 2Global Neurodegenerative Diseases Market 2015-2019 - Reformulation of Marketed Drugs 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3
... Inc. ( www.bendresearch.com ), a leading independent drug-formulation development and ... Jim Nightingale, who has worked at the company since 1993, ... Nightingale will succeed Rod Ray, who will ... (CEO) and chairman of the board of directors. ...
... Mass., July 27, 2011 Magellan Biosciences, a ... testing easier, more cost-effective, and less labor intensive, ... Atlanta yesterday at the AACC Clinical Lab Expo. ... laboratories seeking to improve the workflow efficiency, cost-effectiveness, ...
Cached Medicine Technology:Bend Research Inc. Names New President 2Magellan's Dynex® Agility™ ELISA Processor Dramatically Reduces Laboratory Time and Labor in Diagnostic Testing While Ensuring the Most-Accurate Results 2Magellan's Dynex® Agility™ ELISA Processor Dramatically Reduces Laboratory Time and Labor in Diagnostic Testing While Ensuring the Most-Accurate Results 3
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve...
Ideal for short scleral tunnel and trabecular meshwork incisions...
Medicine Products: